Search - tctmd.com

Displaying 681 - 700 of 806

Sort: Relevancy | Date

Presentation TCT 2012

XIMA: A Prospective, Randomized Trial of Everolimus-Eluting Stents vs. Bare-Metal Stents in Octogenarians

Presenter: Adam de Belder

October 26, 2012

Presentation TCT 2012

Coronary Complication Spectacle: From Air Emboli to Dislodged Stents to No Reflow, Perforations, and More

Presenter: John Douglas Jr

October 26, 2012

Presentation TCT 2012

Reflections on Coronary Stents: From Bare Metal to Drug-Eluting to Bioabsorbable: My Personal Delights and Dilemmas

Presenter: Antonio Colombo

October 26, 2012

Presentation TCT 2012

ISAR-DESIRE 3: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons vs. Paclitaxel-Eluting Stents vs. Balloon Angioplasty for Restenosis of Limus-Eluting Coronary Stents

Presenter: Robert Byrne

October 26, 2012

Presentation TCT 2012

Will Polymer-Free DES Be Safer Than Bare Metal Stents?

Presenter: Philip Urban

October 25, 2012

Presentation TCT 2012

TWENTE 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents

Presenter: Clemens von Birgelen

October 25, 2012

Presentation TCT 2012

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Ken Kozuma

October 25, 2012

Presentation TCT 2012

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

Presenter: Francesco Burzotta

October 25, 2012

Presentation TCT 2012

When Is PCI Justified in Complex (Non-Left Main) Multivessel Disease with Current Drug-Eluting Stents?

Presenter: Dean Kereiakes

October 25, 2012

Presentation TCT 2012

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Lisette Okkels Jensen

October 25, 2012

Presentation TCT 2012

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Patrick Serruys

October 25, 2012

Presentation TCT 2012

EXAMINATION 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Bare Metal Stents in Patients with ST-Segment Elevation Myocardial Infarction

Presenter: Manel Sabate

October 25, 2012

Presentation TCT 2012

Case 3: A Complex Bifurcation with Two or More Stents(Culotte Stenting)

Presenter: John Ormiston

October 25, 2012

Presentation TCT 2012

Case 2: A Complex Bifurcation with Two Stents (T-Stenting)

Presenter: David Rizik

October 25, 2012

Presentation TCT 2012

One or Two Stents: And How to Avoid Complications

Presenter: Kenneth Chin

October 24, 2012

Presentation TCT 2012

ISAR-LEFT MAIN 2: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents in Patients with Unprotected Left Main Disease

Presenter: Julinda Mehilli

October 24, 2012

Presentation TCT 2012

Case Presentation 4: AUC and the Elephant in the Room: Unnecessary Stents

Presenter: Larry Dean

October 24, 2012

Presentation TCT 2012

Bioabsorbable Stent Components and Stents

Presenter: Shigeru Saito

October 24, 2012

Presentation TCT 2012

Bifurcation Lesion Stenting: Impact of Stent Geometry and Technique on Outcomes (and Potential of Dedicated Bifurcation Stents)

Presenter: John Ormiston

October 24, 2012

Presentation TCT 2012

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Presenter: Hyeon-Cheol Gwon

October 24, 2012

Advertisement

XIMA: A Prospective, Randomized Trial of Everolimus-Eluting Stents vs. Bare-Metal Stents in Octogenarians

Coronary Complication Spectacle: From Air Emboli to Dislodged Stents to No Reflow, Perforations, and More

Reflections on Coronary Stents: From Bare Metal to Drug-Eluting to Bioabsorbable: My Personal Delights and Dilemmas

ISAR-DESIRE 3: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons vs. Paclitaxel-Eluting Stents vs. Balloon Angioplasty for Restenosis of Limus-Eluting Coronary Stents

Will Polymer-Free DES Be Safer Than Bare Metal Stents?

TWENTE 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

When Is PCI Justified in Complex (Non-Left Main) Multivessel Disease with Current Drug-Eluting Stents?

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

EXAMINATION 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Bare Metal Stents in Patients with ST-Segment Elevation Myocardial Infarction

Case 3: A Complex Bifurcation with Two or More Stents(Culotte Stenting)

Case 2: A Complex Bifurcation with Two Stents (T-Stenting)

One or Two Stents: And How to Avoid Complications

ISAR-LEFT MAIN 2: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents in Patients with Unprotected Left Main Disease

Case Presentation 4: AUC and the Elephant in the Room: Unnecessary Stents

Bioabsorbable Stent Components and Stents

Bifurcation Lesion Stenting: Impact of Stent Geometry and Technique on Outcomes (and Potential of Dedicated Bifurcation Stents)

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content